Moderna (MRNA) Misses Q3 EPS by $1.35, Revenue Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Moderna (MRNA) Shares Plunge 13% on EPS and Revenue Miss and Slashed Covid-19 Vaccine Sales Guidance
November 4, 2021 8:31 AM EDTShares of Moderna (NASDAQ: MRNA) are down more than 13% in pre-open Thursday after the company delivered disappointing Q3 results and guidance.
Moderna reported Q3 EPS of $7.70, a handy miss compared to the analyst estimate of $9.05. Revenue for the quarter came in at $5 billion versus the consensus estimate of $6.21 billion.
Shares were further hit by the... More
